Amarantus Bioscience Holdings Inc (AMBS)

[JJAAMMAANN]

So, the Chinese are on board???

http://ih.advfn.com/p.php?pid=nmona&article=70181251

Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the
Treatment of Parkinson’s Disease



- Patent issuance will provide intellectual property protection in China for protein therapy,
gene therapy and cell therapy applications of MANF -



SAN FRANCISCO, CA – January 29, 2016 – Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced the issuance of Chinese patent number ZL2009801163060 entitled “Neurodegenerative Disorders” covering the use of MANF for the treatment of Parkinson’s disease and other neurodegenerative conditions. The claims issued extend patent coverage for MANF protein therapy, gene therapy and cell therapy applications into 2029.



“The Chinese market represents a potential significant market opportunity for Amarantus,” said Gerald E. Commissiong, President & CEO of Amarantus. “MANF has demonstrated proof of concept in various efficacy and delivery animal models of Parkinson’s disease. Going forward, the Company will look to partner the development of MANF with a group in China capable of bringing this technology to market in that region.”



The key claim issued in this patent is “Use of MANF for the manufacture of a medicament for administration to the substantia nigra region of the brain for treating Parkinson’s disease.” The substantia nigra is a key area of the brain where dopamine producing neurons degenerate in Parkinson’s disease. Additional claims covering combinations of MANF and other therapeutic moieties were also granted. This patent adds to Amarantus’ extensive international intellectual property portfolio covering compositions of matter, methods of use and formulations for MANF.


About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)

MANF (mesencephalic-astrocyte-derived neurotrophic factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's lead indications are retinitis pigmentosa (RP) and retinal artery occlusion (RAO), and additional indications including Parkinson's disease, diabetes, and Wolfram's syndrome are currently being evaluated. Further applications for MANF may include Alzheimer's disease, traumatic brain injury (TBI), myocardial infarction, antibiotic-induced ototoxicity and certain other rare orphan diseases currently under consideration.